In the current study, the focus on AML is driven by both the overexpression of Mcl-1 in AML and the prior demonstration of potent anti-AML activity of compound 8l (IC50 = 1.5 μM)(Pathan et al. 2023). The gene discussed is MCL1; the disease is acute myeloid leukemia.